SBC Medical Group Holdings
SBCNASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $5.29 Prior regular-session close from the quote source.
- $5.12–$5.31 Regular-session low and high so far today.
- 111.6K Regular-session shares traded · Nov 11, 4:00 PM ET.
- Nov 13 projected Projected for 2026-11-13 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $2.78–$5.79 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own SBC if SBC Medical Group can generate durable cash and shareholder optionality by operating high-margin outpatient physician clinics while using a strong cash position to buy growth, but that outcome depends on stable reimbursements, patient volumes.
SBC price history
Loading recent earnings…
Investment thesis
What must happen next
SBC's clinic operating model delivers structurally high margins (pricing / service mix / low variable cost) so operating income will remain a large percentage of revenue even if top-line growth is modest.StrengtheningMateriality: High
operating_income: 70,660,066 USD (FY2023). If margins are durable, modest revenue growth still produces large free cash flow and optionality for acquisitions or shareholder returns; if margins compress, reported earnings will not translate into value.
Watch: A significant payer reimbursement cut or contractual rate re-pricing that reduces clinic pricing.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
operating_income: 70,660,066 USD (FY2023).
Open source ↗SBC has accumulated a large cash balance that gives management the ability to pursue M&A or other value-creating deployments without near-term external financing, creating an actionable optionality channel for growth.StrengtheningMateriality: High
cash: 485,564 USD (2022) -> 103,022,932 USD (2023) -> 125,044,092 USD (2024) -> 163,773,838 USD (2025) — large, sustained build. If management uses cash for accretive clinic buys or operational investments, the company can grow revenue and scale margins; if cash is transitory or used inefficiently, the balance sheet advantage disappears.
Watch: The cash increase is from one-time financing/transaction proceeds that are earmarked for specific obligations or are refundable.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
cash: 485,564 USD (2022) -> 103,022,932 USD (2023) -> 125,044,092 USD (2024) -> 163,773,838 USD (2025) — large, sustained build.
Open source ↗SBC's revenue is sufficiently concentrated or exposed to patient-volume / contract variability that top-line can swing materially year-to-year; sustaining growth requires patient/contract wins or geographic expansion.HoldingMateriality: Medium
revenue: 193,542,423 USD (FY2023) -> 205,415,542 USD (FY2024) -> 173,607,489 USD (FY2025) — material decline in 2025. Volatile or concentrated revenue means earnings can be lumpy and growth (not margin) will be the main driver of valuation gains; protecting the thesis requires visible diversification or repeatable patient intake gains.
Watch: Major clinic or contract loss in a core market or a competitor winning exclusive referral arrangements.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
revenue: 193,542,423 USD (FY2023) -> 205,415,542 USD (FY2024) -> 173,607,489 USD (FY2025) — material decline in 2025.
Open source ↗SBC's conversion of operating profits into cash is inconsistent — working-capital swings or one-time items can materially alter operating cash flow even when operating income is stable, so reliable free cash flow is not yet proven.StrengtheningMateriality: Medium
operating_cash_flow: 50,670,322 USD (FY2023) -> 20,582,933 USD (FY2024) -> 24,668,496 USD (FY2025) — large drop from 2023 despite similar operating income. If cash conversion remains volatile, the firm may need to retain cash or raise capital rather than fund acquisitions/returns; reliable conversion would validate the optionality provided by the cash balance.
Watch: If the drop is due to recurring structural working capital (e.g., slower collections from payers) rather than one-off timing, conversion may remain weak.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
operating_cash_flow: 50,670,322 USD (FY2023) -> 20,582,933 USD (FY2024) -> 24,668,496 USD (FY2025) — large drop from 2023 despite similar operating.
Open source ↗SBC's equity and asset base has strengthened materially since 2022, reducing solvency risk and enabling investment; this change appears structural (capital raise or retained earnings) rather than transient.StrengtheningMateriality: Medium
equity: -3,358,671 USD (FY2022) -> 142,159,177 USD (FY2023) -> 195,109,157 USD (FY2024) -> 248,282,196 USD (FY2025). A stronger balance sheet lowers financial risk and creates runway for M&A or capital-intensive growth; if the improvement reverses, liquidity and strategic optionality shrink.
Watch: Equity increases driven mainly by share issuance could dilute per-share economics if not paired with accretive deployment.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
equity: -3,358,671 USD (FY2022) -> 142,159,177 USD (FY2023) -> 195,109,157 USD (FY2024) -> 248,282,196 USD (FY2025).
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
SBC's clinic operating model delivers structurally high margins (pricing / service mix / low variable cost) so operating income will remain a large percentage of revenue even if top-line growth is modest. If margins are durable, modest revenue growth still produces large free cash flow and optionality for acquisitions or shareholder returns; if margins compress, reported earnings will not translate into value.
SBC has accumulated a large cash balance that gives management the ability to pursue M&A or other value-creating deployments without near-term external financing, creating an actionable optionality channel for growth. If management uses cash for accretive clinic buys or operational investments, the company can grow revenue and scale margins; if cash is transitory or used inefficiently, the balance sheet advantage disappears.
SBC's revenue is sufficiently concentrated or exposed to patient-volume / contract variability that top-line can swing materially year-to-year; sustaining growth requires patient/contract wins or geographic expansion. Volatile or concentrated revenue means earnings can be lumpy and growth (not margin) will be the main driver of valuation gains; protecting the thesis requires visible diversification or repeatable patient intake gains.
SBC's conversion of operating profits into cash is inconsistent — working-capital swings or one-time items can materially alter operating cash flow even when operating income is stable, so reliable free cash flow is not yet proven. If cash conversion remains volatile, the firm may need to retain cash or raise capital rather than fund acquisitions/returns; reliable conversion would validate the optionality provided by the cash balance.
SBC's equity and asset base has strengthened materially since 2022, reducing solvency risk and enabling investment; this change appears structural (capital raise or retained earnings) rather than transient. A stronger balance sheet lowers financial risk and creates runway for M&A or capital-intensive growth; if the improvement reverses, liquidity and strategic optionality shrink.
All standing thesis claims
Original report summary
SBC Medical Group can generate durable cash and shareholder optionality by operating high-margin outpatient physician clinics while using a strong cash position to buy growth, but that outcome depends on stable reimbursements, patient volumes.
Bull case and bear case
Bull case and bear case for SBC Medical Group Holdings
Where the evidence on SBC Medical Group Holdings stands: Holding on the latest evidence (Nov 10, 2026). Of its 5 thesis points, 4 strengthening and 1 holding.
Bull case: what the evidence supports
SBC's clinic operating model delivers structurally high margins (pricing / service mix / low variable cost) so operating income will remain a large percentage of revenue even if top-line growth is modest.
SBC has accumulated a large cash balance that gives management the ability to pursue M&A or other value-creating deployments without near-term external financing, creating an actionable optionality channel for growth.
SBC's revenue is sufficiently concentrated or exposed to patient-volume / contract variability that top-line can swing materially year-to-year; sustaining growth requires patient/contract wins or geographic expansion.
SBC's conversion of operating profits into cash is inconsistent — working-capital swings or one-time items can materially alter operating cash flow even when operating income is stable, so reliable free cash flow is not yet proven.
SBC's equity and asset base has strengthened materially since 2022, reducing solvency risk and enabling investment; this change appears structural (capital raise or retained earnings) rather than transient.
Bear case: what would count against it
A significant payer reimbursement cut or contractual rate re-pricing that reduces clinic pricing.
The cash increase is from one-time financing/transaction proceeds that are earmarked for specific obligations or are refundable.
Major clinic or contract loss in a core market or a competitor winning exclusive referral arrangements.
Thesis-Break Engine
Thesis-break watch · SBC Medical Group Holdings
No break has crossed SBC Medical Group Holdings’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
SBC Medical Group Holdings filed an SEC 8-K on 2026-08-13: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedDelisting notice or listing-rule failure.
SBC Medical Group Holdings filed an SEC 8-K on 2026-07-14: Delisting notice or listing-rule failure. It is a dated development that tests the current thesis.
- MixedDirector or principal officer change.
SBC Medical Group Holdings filed an SEC 8-K on 2026-05-20: Director or principal officer change. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- A significant payer reimbursement cut or contractual rate re-pricing that reduces clinic pricing.
- The cash increase is from one-time financing/transaction proceeds that are earmarked for specific obligations or are refundable.
- Major clinic or contract loss in a core market or a competitor winning exclusive referral arrangements.
- If the drop is due to recurring structural working capital (e.g., slower collections from payers) rather than one-off timing, conversion may remain weak.
- Equity increases driven mainly by share issuance could dilute per-share economics if not paired with accretive deployment.
SBC news
Loading headlines…
Financial statements
SBC income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
SBC: quick answers
- When does SBC Medical Group Holdings (SBC) report earnings next?
- SBC Medical Group Holdings's next results are projected for November 13, 2026, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on August 13, 2026. Earnings calendar
- What is SBC's short interest?
- As of October 30, 2026, 840,714 SBC shares were sold short, 0.82% of its shares outstanding, up 12.0% from the count before. At the stock's average daily volume that is 4.6 days to cover. FINRA publishes the count twice a month. SBC short interest history
